Vygenerované: 09.03.2026 23:00:10
Súhrn: TOPLINE: High-intensity circuit training (HICT) combined with a sleep health (SH) intervention was linked to greater improvements in sleep outcomes and cardiometabolic health compared with either intervention alone in sedentary young women with poor SH, a new study showed - HICT included three laboratory-based body weight training sessions per week; the SH intervention included a weekly individualized counseling session and use of a digital cognitive behavioral therapy for insomnia app - Secondary outcomes included changes in cardiometabolic health indicators, such as levels of cholesterol, triglycerides, and adiponectin.
Doplnenie: All participants were randomly assigned evenly to receive the combined HICT-SH intervention, HICT alone, the SH intervention alone, or no intervention (control group) — which consisted of following their original lifestyle.
Súhrn: Sinusitis is not commonly cited as side effect of GLP-1s; however, some research has shown that symptoms such as nasal congestion, postnasal drip, and sinus discomfort could be tied to GLP-1 use The most common form of sinusitis is acute sinusitis, and the most common etiology is viral, said Christie Barnes, MD, associate professor in the University of Nebraska Medical Center’s Department of Otolaryngology-Head and Neck Surgery in Omaha, Nebraska Sinus headaches and pressure, nasal irritation and related symptoms, as well as sinusitis are common issues affecting patients in primary-care practices.
Doplnenie: Although these symptoms have not been definitively established as direct side effects of GLP medications, they could cause sinus complications and warrant clinical attention.
Súhrn: Deucravacitinib (Sotyktu) — an oral, selective tyrosine kinase 2 (TYK2) inhibitor — has received FDA approval for the treatment of adults with active psoriatic arthritis (PsA), the drug’s manufacturer Bristol Myers Squibb announced Deucravacitinib was first approved by the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy POETYK PsA-1 tested deucravacitinib vs placebo in 670 adults who were naive to biologic disease-modifying anti-rheumatic drugs (bDMARDs), and POETYK PsA-2 tested deucravacitinib vs placebo in 624 adults who were naive to bDMARDs or had previously received TNF-alpha inhibitor treatment.
Doplnenie: It has subsequently been approved for plaque psoriasis in the European Union, China, Japan, and other countries.
Súhrn: Exercise improves overall health and slows the progression of aging-related comorbidities in PWH, but understanding of the feasibility and effects of exercise in this population is limited, lead author Jing Sun, MD, MPH, PhD, associate research professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health in Baltimore, told Medscape Medical News Sun and colleagues designed a study to evaluate the impact of a 16-week exercise intervention on muscle DNA methylation in older PWH using data from the HEALTH trial The HEALTH study was a randomized controlled trial comparing changes in physical function and fatigue between high-intensity interval training and continuous moderate-intensity training in PWH aged 50 years or older over a 16-week period.
Doplnenie: Sun and colleagues designed a study to evaluate the impact of a 16-week exercise intervention on muscle DNA methylation in older PWH using data from the HEALTH trial.
Súhrn: * The patients treated with the drug, tilrekimig, saw asignificant reduction in symptoms after 16 weeks and the drugwas well tolerated with a favorable safety profile in the study,Pfizer said * The drug is currently being tested in patients withmoderate to severe atopic dermatitis or eczema, a skin diseasethat causes itching, widespread rashes and inflammation that candisrupt daily activities * Pfizer plans to develop the drug for asthma and chronicobstructive pulmonary disease.
Doplnenie: * Seigerman said the readout gives Pfizer another potentialcatalyst as it works to rebuild momentum across its pipeline,but cautioned that more detailed safety and placebo‑responsedata will be critical.